drugset
Drugs / Nasovac-S
last change May 2019 re-read 9 days ago

Nasovac-S

Vaccine

Developed for
influenza
Investigated by
London School of Hygiene and Tropical Medicine · National Institute for Public Health and the Environment (RIVM) · Public Health England · University of Edinburgh · University of Oxford

Trials 1

today NCT02972957 · Ph 4
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02972957 Jan 2017 → Dec 2018 influenza London School of Hygiene and Tropical Medicine Completed Missed primary

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Nasovac-S ClinicalTrials.gov intervention name — accepted as the source's own label NCT02972957 ↗
Modality Vaccine “intranasal live attenuated influenza vaccine (LAIV; Nasovac-S, Serum Institute of India Pvt. Ltd.)” NCT02972957 ↗